home All News open_in_new Full Article

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE […]


today 20 h. ago attach_file Culture

attach_file Economics
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Society
attach_file Culture
attach_file Sport
attach_file Culture
attach_file Culture
attach_file Culture
attach_file Economics
attach_file Society
attach_file Culture
attach_file Culture
attach_file Economics
attach_file Other
attach_file Sport
attach_file Culture
attach_file Society


ID: 640681548
Add Watch Country

arrow_drop_down